ISO 14155-2:2003

Clinical investigation of medical devices for human subjects — Part 2: Clinical investigation plans

This part of EN ISO 14155 provides requirements for the preparation of a Clinical Investigation Plan (CIP) for the clinical investigation of medical devices. The compilation of a CIP in accordance with the requirements of this standard and adherence to it will help in optimising the scientific validity and reproducibility of the results of a clinical investigation. This Standard does not apply to in vitro diagnostic medical devices.

Investigation clinique des dispositifs médicaux pour sujets humains — Partie 2: Plans d'investigation clinique

General Information

• Status: Withdrawn
• Publication Date: 15-May-2003
• Withdrawal Date: 15-May-2003
• ICS: 11.100.20 - Biological evaluation of medical devices
• Technical Committee: ISO/TC 194 - Biological and clinical evaluation of medical devices
• Drafting Committee: ISO/TC 194/WG 4 - Clinical investigations of medical devices in humans
• Current Stage: 9599 - Withdrawal of International Standard
• Completion Date: 21-Jan-2011

Relations

• Revised: ISO 14155:2011 - Clinical investigation of medical devices for human subjects — Good clinical practice
• Effective Date: 15-Apr-2008
• Consolidates: ISO 6589:1983 - Joints in building — Laboratory method of test for air permeability of joints
• Effective Date: 06-Jun-2022
• Revises: ISO 14155:1996 - Clinical investigation of medical devices
• Effective Date: 15-Apr-2008

Standards Content (Sample)

INTERNATIONAL ISO
STANDARD 14155-2
First edition
2003-05-15

Clinical investigation of medical devices
for human subjects —
Part 2:
Clinical investigation plans
Investigation clinique des dispositifs médicaux pour sujets humains —
Partie 2: Plans d'investigation clinique




Reference number
ISO 14155-2:2003(E)
©
ISO 2003

---------------------- Page: 1 ----------------------
ISO 14155-2:2003(E)
PDF disclaimer
This PDF file may contain embedded typefaces. In accordance with Adobe's licensing policy, this file may be printed or viewed but
shall not be edited unless the typefaces which are embedded are licensed to and installed on the computer performing the editing. In
downloading this file, parties accept therein the responsibility of not infringing Adobe's licensing policy. The ISO Central Secretariat
accepts no liability in this area.
Adobe is a trademark of Adobe Systems Incorporated.
Details of the software products used to create this PDF file can be found in the General Info relative to the file; the PDF-creation
parameters were optimized for printing. Every care has been taken to ensure that the file is suitable for use by ISO member bodies. In
the unlikely event that a problem relating to it is found, please inform the Central Secretariat at the address given below.


©  ISO 2003
All rights reserved. Unless otherwise specified, no part of this publication may be reproduced or utilized in any form or by any means,
electronic or mechanical, including photocopying and microfilm, without permission in writing from either ISO at the address below or
ISO's member body in the country of the requester.
ISO copyright office
Case postale 56 • CH-1211 Geneva 20
Tel. + 41 22 749 01 11
Fax + 41 22 749 09 47
E-mail [e-mail]
Web www.iso.org
Published in Switzerland

ii © ISO 2003 – All rights reserved

---------------------- Page: 2 ----------------------
ISO 14155-2:2003(E)
Foreword
ISO (the International Organization for Standardization) is a worldwide federation of national standards bodies
(ISO member bodies). The work of preparing International Standards is normally carried out through ISO
technical committees. Each member body interested in a subject for which a technical committee has been
established has the right to be represented on that committee. International organizations, governmental and
non-governmental, in liaison with ISO, also take part in the work. ISO collaborates closely with the
International Electrotechnical Commission (IEC) on all matters of electrotechnical standardization.
International Standards are drafted in accordance with the rules given in the ISO/IEC Directives, Part 2.
The main task of technical committees is to prepare International Standards. Draft International Standards
adopted by the technical committees are circulated to the member bodies for voting. Publication as an
International Standard requires approval by at least 75 % of the member bodies casting a vote.
Attention is drawn to the possibility that some of the elements of this document may be the subject of patent
rights. ISO shall not be held responsible for identifying any or all such patent rights.
ISO 14155-2 was prepared by the European Committee for Standardization (CEN) in collaboration with
Technical Committee ISO/TC 194, Biological evaluation of medical devices, in accordance with the
Agreement on technical cooperation between ISO and CEN (Vienna Agreement).
Throughout the text of this document, read ".this European Standard." to mean ".this International
Standard.".
This first edition, together with the first edition of ISO 14155-1, cancels and replaces ISO 14155:1996, which
has been technically revised.
ISO 14155 consists of the following parts, under the general title Clinical investigation of medical devices for
human subjects:
— Part 1: General requirements
— Part 2: Clinical investigation plans
For the purposes of this part of ISO 14155, the CEN annex regarding fulfilment of European Council
Directives has been removed.
© ISO 2003 – All rights reserved iii

---------------------- Page: 3 ----------------------
ISO 14155-2:2003(E)


Contents
Page
Foreword.v
Introduction .vi
1 Scope .1
2 Normative references .1
3 Terms and definitions.1
4 Requirements .2
4.1 General.2
4.2 Clinical Investigation Plan (CIP).2
4.3 General information.2
4.3.1 Identification of the clinical investigation plan.2
4.3.2 Clinical investigators, principal clinical investigator, co-ordinating clinical investigator,
investigation centres/site(s) .2
4.3.3 Sponsor.2
4.3.4 Monitoring arrangements.2
4.3.5 Data and quality management.2
4.3.6 An overall synopsis of the clinical investigation.3
4.3.7 Approval and agreement to the clinical investigation plan.3
4.4 Identification and description of the medical device to be investigated .3
4.5 Preliminary investigations and justification of the study.3
4.5.1 Literature review .3
4.5.2 Preclinical testing .3
4.5.3 Previous clinical experience.4
4.5.4 Device risk analysis and risk assessment .4
4.6 Objectives of the clinical investigation .4
4.7 Design of the clinical investigation.4
4.8 Statistical considerations .5
4.9 Deviations from the clinical investigation plan .6
4.10 Amendments to the clinical investigation plan .6
4.11 Adverse events and adverse device effects .6
4.12 Early termination or suspension of the investigation.6
4.13 Publication policy .6
4.14 Case Report Forms.7
Annex A (informative) Case Report Forms .8
Bibliography .9
iv © ISO 2003 – All rights reserved

---------------------- Page: 4 ----------------------
ISO 14155-2:2003(E)


Foreword
This document (EN ISO 14155-2:2003) has been prepared by Technical Committee CEN /TC 258 "Clinical
investigation of medical devices", the secretariat of which is held by AFNOR, in collaboration with Technical
Committee ISO/TC 194 "Biological evaluation of medical devices".
This European Standard shall be given the status of a national standard, either by publication of an identical text or
by endorsement, at the latest by November 2003, and conflicting national standards shall be withdrawn at the latest
by November 2003.
This document has been prepared under a mandate given to CEN by the European Commission and the European
Free Trade Association, and supports essential requirements of EU Directive(s).
Annex A is informative.
According to the CEN/CENELEC Internal Regulations, the national standards organizations of the following
countries are bound to implement this European Standard: Austria, Belgium, Czech Republic, Denmark, Finland,
France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Luxembourg, Malta, Netherlands, Norway, Portugal,
Slovakia, Spain, Sweden, Switzerland and the United Kingdom.
© ISO 2003 – All rights reserved v

---------------------- Page: 5 ----------------------
ISO 14155-2:2003(E)


Introduction
This standard is the second part of EN ISO 14155 "Clinical investigation of medical devices for human subjects",
and should be read in conjunction with that standard.
The standard is intended to assist manufacturers, sponsors, monitors and clinical investigators in the design and
conduct of clinical investigations. It is also intended to assist regulatory bodies and ethics committees in their roles
of reviewing Clinical Investigation Plans (CIP). The CIP is a framework within which appropriate experience, insight,
judgement, qualification and education need to be applied. The scientific rigour of a CIP can be verified and
possibly improved by an independent review of the CIP.
vi © ISO 2003 – All rights reserved

---------------------- Page: 6 ----------------------
ISO 14155-2:2003(E)
1 Scope
This part of EN ISO 14155 provides requirements for the preparation of a Clinical Investigation Plan (CIP) for the
clinical investigation of medical devices. The compilation of a CIP in accordance with the requirements of this
standard and adherence to it will help in optimising the scientific validity and reproducibility of the results of a
clinical investigation.
This Standard does not apply to in vitro diagnostic medical devices.
2 Normative references
This European Standard incorporates by dated or undated reference, provisions from other publications. These normative
references are cited at the appropriate places in the text, and the publications are listed hereafter. For dated references,
subsequent amendments to or revisions of any of these publications apply to this European Standard only when incorporated in
it by amendment or revision. For undated references the latest edition of the publication referred to applies (including
amendments).
EN ISO 14155-1:2003, Clinical investigation of medical devices for human subjects — Part 1: General
requirements. (ISO 14155-1:2001)
3 Terms and definitions
For the purposes of this European Standard, the terms and definitions given in EN ISO 14155-1:2003 and the
following apply.
3.1
end point - primary
principal indicator measured or determined to assess the primary objective of a clinical investigation
3.2
end point - secondary
indicator measured or determined in addition to the primary end-point to assess some other objective of a clinical
investigation
3.3
point of enrolment
time at which, following recruitment, a subject has signed the informed consent form and is regarded as part of the
study population
3.4
follow-up period
period of the clinical investigation after the application of the device under investigation in each subject during
which the effects of the device are observed
3.5
recruitment
process of identifying subjects who may be suitable for enrolment into the clinical investigation
© ISO 2003 – All rights reserved 1

---------------------- Page: 7 ----------------------
ISO 14155-2:2003(E)
4 Requirements
4.1 General
All requirements of EN ISO 14155-1 apply.
4.2 Clinical Investigation Plan (CIP)
The CIP shall be a document developed by the sponsor and the clinical investigator(s). The CIP shall be designed
in such a way as to optimise the scientific validity and reproducibility of the results of the study in accordance with
current clinical knowledge and practice so as to fulfil the objectives of the investigation.
The CIP shall include the information specified in the subsequent clauses. Alternatively, if the required information
is written in other documentation, for example the clinical investigator’s brochure or the sponsor’s standard
operating procedures, such documentation shall be referenced in the CIP and shall be made available on request.
In the event of the sponsor deciding that any requirement given in 4.3 to 4.10 is not applicable, relevant or
appropriate, a clear statement justifying the omission of the information specified shall be provided on each
occasion.
4.3 General information
4.3.1 Identification of the clinical investigation plan
The CIP and any amended version shall state the title of the clinical investigation and its reference number. The
CIP shall also include a version/issue number and date to ensure that it may be traced to the signatories (see
4.3.7). Each page of the CIP shall be referenced with the version number.
4.3.2 Clinical investigators, principal clinical investigator, co-ordinating clinical investigator, investigation
centres/site(s)
The CIP shall state or refer to a list of the name(s), address(es), and professional position(s) of the clinical
investigator(s), of the principal clinical investigator(s) and co-ordinating clinical investigator if appointed. The CIP
shall document the name(s) and address(es) of the Institution(s) in which the clinical investigation will be
conducted. Where it may affect the validity of the clinical investigation, the name(s) and address(es) of other
establishments or persons involved in patient management, and associated testing and analysis shall be given.
4.3.3 Sponsor
The CIP shall state the name and address of the sponsor of the clinical investigation.
NOTE If the sponsor is not resident in the country (countries) in which the clinical investigation is to be carried out, the
name and address of a representative in that country (those countries) may be required according to national or regional
regulations.
4.3.4 Monitoring arrangements
The CIP shall state the monitoring arrangements to be followed during the investigation and the planned extent of
source data verification.
4.3.5 Data and quality management
The CIP shall describe or refer to the procedures for database management, treatment of data, source data
verification, data archiving, retention period and other aspects of quality assurance as appropriate.
2 © ISO 2003 – All rights reserved

---------------------- Page: 8 ----------------------
ISO 14155-2:2003(E)
4.3.6 An overall synopsis of the clinical investigation
The CIP shall provide a sum
...